PsychedelicNewsBreaks

WednesdayOct 06, 2021 10:53 am

PsychedelicNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Delic Labs Moves Forward with Strategic Steps toward Commercialization

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced that Delic Labs, which is part of the Delic Corp. family, has applied for a Health Canada 56 Research Exemption. Approval of the application allows Delic Labs scientists to perform research and tests on compounds in addition to psychedelic mushrooms, which it currently holds a 56 research exemption to study. The new application would allow the lab to study substances such as MDMA and LSD. The lab has also submitted an application for a dealer’s license. These steps are part of a strategic plan leading toward…

Continue Reading

TuesdayOct 05, 2021 10:01 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Keynote Speaker for Upcoming Premiere Psychedelic and Wellness Event

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced the keynote speaker for its upcoming Meet Delic event, a revolutionary, two-day immersive edutainment experience designed to bring together the world's leading psychedelic and wellness thought and business leaders. Dr. Molly Maloof, MD, will speak at the premiere event, which will take place on Nov. 6, 2021. Maloof has an impressive background of working with investors, entrepreneurs, and executives to optimize their health. She has also consulted with an estimated 45 companies that operate in the digital health, consumer health and biotechnology industries. Cofounder of the…

Continue Reading

FridayOct 01, 2021 11:32 am

PsychedelicNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) to Host Live Event Highlighting New Potential Treatments for Alcohol Use Disorder, Binge Drinking

Clearmind Medicine (CSE: CMND), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that it will host Psychedelics for Alcoholism. The live virtual event highlights new potential treatments for alcohol use disorder and binge drinking. Registration is open and free to all for the online event, which is slated to start at 12 p.m. ET/9 a.m. PT on Oct. 20, 2021. The event will feature brief speaker presentations followed by a discussion with a question-and-answer session. The company has curated a panel of scientists, thought…

Continue Reading

FridayOct 01, 2021 10:11 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Appoints New Executives, Promotes Team Members

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has named two new executive team members. The company has named Dr. Amir Inamdar as the chief medical officer for its European operations and Dr. Geoff Varty as the  new head of research & development. In addition, the company has made some internal promotions, naming Lori Challenger as chief compliance, ethics & administrative officer and Robert Mino as general counsel. A trained psychiatrist and pharmaceutical physician with more than two decades of clinical and drug-development experience, Inamdar has deep expertise in progressing numerous drugs from preclinical development…

Continue Reading

ThursdaySep 30, 2021 1:12 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Enters First-of-Its-Kind Partnership with Paradigm Healthcare

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced a first-of-its-kind partnership with Paradigm Healthcare, an independent clinical laboratory located in St. Simons, Georgia, with a focus on high complexity, clinical toxicology, to bring state-of-the-art testing to Ketamine Infusion Centers LLC (“KIC”). Under the partnership, KIC will have access to Paradigm’s Benchmark UDT(TM) toxicology solution that utilizes LC/MS/MS test methods to identify and accurately measure drug compounds in the body, ensuring the highest quality toxicology results and clinically relevant test data to support medical decision making. “Paradigm’s Benchmark testing platform brings state-of-the-art drug testing…

Continue Reading

TuesdaySep 28, 2021 10:11 am

PsychedelicNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Meet Delic to Showcase Lamar Odom’s Path to Healing with Psychedelics

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that two-time NBA champion Lamar Odom will headline Meet Delic on Nov. 7, 2021. Odom’s professional basketball career spanned 15 years, including seven as a forward with the Los Angeles Lakers that earned him 2009 and 2010 NBA championships. Odom joined LeBron James, Allen Iverson, Tim Duncan and Dwayne Wade as members of the gold-winning U.S. men’s basketball team at the 2004 Athens Olympics. In 2015, Odom was hospitalized in Las Vegas after a near-death overdose resulting in multiple seizures, strokes and a coma. An upcoming documentary…

Continue Reading

MondaySep 27, 2021 11:57 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Working to Bring Psychedelic Treatments Closer to the People

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is contributing to the ongoing conversation around the use of psychedelics in the field of medicine, thereby stamping its position as a leader in the psychedelic renaissance. This follows efforts by the scientific community in the 21st century to prove the potential of psychedelics to rewire or repair circuits in the brain. Specifically, Tryp is bringing light to psilocybin usage in diseases with high unmet needs, including chronic pain, through its Psilocybin-For Neuropsychiatric Disorders (TM) (“PFN”) program. “With its three strategic initiatives — develop, protect and monetize — Tryp remains committed to utilizing FDA’s…

Continue Reading

FridaySep 24, 2021 1:26 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Garners Attention as ‘Emerging Leader in the Psychedelic Therapeutics Space’

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its Q1 2021 operational and financial report for the period ended June 30, 2021. The biotech company hit several milestones, including becoming the first psychedelic company to list on the NYSE American LLC stock exchange and raising more than CA$120 million. In addition, Cybin has started the next phase of its digital therapeutics platform, signed an exclusive R&D collaboration agreement with TMS NeuroHealth Centers Inc to establish Mental Health Centers of Excellence, as well as commenced scaling up its…

Continue Reading

WednesdaySep 22, 2021 2:08 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA"). The clinical trial is designed to evaluate the efficacy of TRYP’s clinical candidate, TRP-8802, for the treatment of patients with eating disorders. TRYP is working with Jennifer Miller, MD, from the University of Florida, to conduct the trial as well as evaluate its oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. The IND application outlines specifics in regard to the safety of…

Continue Reading

MondaySep 20, 2021 1:11 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Planned Acquisition of Ketamine Wellness Centers Inc.

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced plans to merge with Ketamine Wellness Centers Arizona LLC (“KWC”), which would create the largest psychedelic wellness chain in the country. The binding merger agreement would create 12 open locations — 10 KWC locations and two Delic locations — with plans in place to open 15 additional clinics in the next 18 months. KWC’s ketamine infusion treatment clinics are located in Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas and Washington; Delic’s clinics are in California and Arizona. “This is a game changer for the future of health and psychedelic wellness in America,” said Delic cofounder and…

Continue Reading